PubMed Health⌕ Search
Home/Archive/PubMed

PubMed · 9014499

Recombinant proteins for therapy.

P Buckel
View original source ↗Export metadata ↓

Abstract

Recombinant therapeutic proteins have become increasingly important over the past ten years. Numerous products derived from 20 different proteins are already on the market. In this review Peter Buckel discusses the issues surrounding the use of recombinant proteins as therapeutic agents. The first generation proteins for therapy all occur naturally in humans. Protein engineering has brought forth a second generation of products with application-specific properties obtained by fusion, mutation or deletion. The third generation of therapeutic proteins is produced by patients themselves after transfer of the relevant genes. The first successful applications of this gene therapy represent a new milestone in medicine.

Explore related subjects

Genetic TherapyHumansProtein EngineeringRecombinant ProteinsJournal ArticleReview

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

P Buckel. 1996. Recombinant proteins for therapy.. https://doi.org/10.1016/s0165-6147(96)01011-5

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed2006

Enhancing tumor radiosensitivity by intracellular delivery of survivin antagonists.

Radiotherapy is frequently applied to control local tumors by mechanisms of direct killing tumor cells and inducing tumor vascular endothelial cells apoptosis. Recently, it has been demonstrated that survivin, an intracellular molecule with anti-apoptotic function, is widely expressed in human malignancies and its expression correlates with radioresistance in several tumors. Moreover, VEGF, which is highly expressed in solid tumors and further up-regulated by irradiation, has been shown to induce survivin expression in both tumor cells and vascular endothelial cells. Thus provide a survival signal to these cells and induce radioresistance to the subsequent irradiation exposure. Knocking down the expression of survivin by RNA interference or transfecting with a gene coding for a dominant negative survivin has been proved to be efficient in enhancing tumor cell radiosensitivity and improving tumor response to radiotherapy. The development of protein transduction technology made it possible to deliver large molecules into mammalian cells. We postulate that dominant negative mutants of survivin could fuse with protein transduction domain and the fusion proteins could cross cellular membranes and generate their biological activity to serve as tumor radiosensilizers. If the hypothesis proved to be practical, it would provide us an alternate method to enhance tumor radiosensitivity and the fusion proteins would be widely applicated in clinical settings because they were safer than gene therapy.

Genetic Therapy↗